Shares of weight loss stocks are trading lower, possibly on continued weakness following recent weight loss data from Roche, which could cause competition concerns for companies in the space.

7/18/24 11:20:16 AM ET

$GPCR

$LLY

$NVO

Biotechnology: Pharmaceutical Preparations

Health Care

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $GPCR alert in real time by email

Shares of weight loss stocks are trading lower, possibly on continued weakness following recent weight loss data from Roche, which could cause competition concerns for companies in the space.

Get the next $GPCR alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$GPCR
$LLY
$NVO

Company	Date	Price Target	Rating	Analyst
Eli Lilly and Company $LLY	11/15/2024	$1000.00	Outperform	Wolfe Research
Eli Lilly and Company $LLY	10/17/2024	$1100.00	Outperform	Bernstein
Structure Therapeutics Inc. $GPCR	9/23/2024	$118.00	Overweight	Morgan Stanley
Eli Lilly and Company $LLY	9/13/2024	$1060.00	Buy	Citigroup
Eli Lilly and Company $LLY	8/12/2024	$1025.00	Hold → Buy	Deutsche Bank
Novo Nordisk A/S $NVO	5/30/2024	$156.00	Buy	Goldman
Structure Therapeutics Inc. $GPCR	5/21/2024	$65.00	Overweight	JP Morgan
Novo Nordisk A/S $NVO	4/12/2024	$163.00	Outperform	BMO Capital Markets

More analyst ratings

$GPCR
$LLY
$NVO
Financials

Live finance-specific insights

Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights
First patients dosed in Phase 2b ACCESS study of GSBR-1290 for obesity Oral small molecule amylin receptor agonist development candidate expected to be selected by the end of 2024 Strong financial position with cash, cash equivalent and short-term investments of $915.3 million expected to fund projected operations and key clinical milestones through at least 2027 Conference Call to discuss GSBR-1290 ACCESS development program today at 4:30 p.m. ET SAN FRANCISCO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today
11/13/24 4:05:00 PM ET
$GPCR
Biotechnology: Pharmaceutical Preparations
Health Care
Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity
Phase 2b ACCESS study designed to evaluate multiple doses up to 120 mg of GSBR-1290 over 36 weeks Comprehensive development program also includes Phase 2 ACCESS II study to evaluate even higher doses of GSBR-1290 over 36 weeks; first patient expected to be dosed by end of 2024 Topline data from both ACCESS and ACCESS II studies expected in the fourth quarter of 2025 Company to host conference call today at 4:30 p.m. Eastern Time SAN FRANCISCO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced the first pati
11/13/24 4:01:00 PM ET
$GPCR
Biotechnology: Pharmaceutical Preparations
Health Care
Lilly reports Q3 2024 financial results highlighted by strong volume-driven revenue growth from New Products
Revenue in Q3 2024 increased 20%, driven by volume growth from Mounjaro and Zepbound, partially offset by $1.42 billion of revenue in Q3 2023 from the sale of rights for the olanzapine portfolio (Zyprexa). Excluding revenue from the olanzapine portfolio, total revenue increased 42%, and non-incretin revenue increased 17%.Q3 2024 EPS increased to $1.07 on a reported basis and $1.18 on a non-GAAP basis, both inclusive of $3.08 of acquired IPR&D charges. 2024 revenue guidance range updated to $45.4 to $46.0 billion. 2024 reported EPS guidance updated to the range of $12.05 to $12.55, and non-GAAP EPS guidance updated to the range of $13.02 to $13.52, both driven by the acquired IPR&D charges in
10/30/24 6:45:00 AM ET
$LLY
Biotechnology: Pharmaceutical Preparations
Health Care

$GPCR
$LLY
$NVO
Leadership Updates

Live Leadership Updates

Asha Therapeutics Awarded Barnett Drug Development Grant by the ALS Association to Advance Novel Intra-Molecular Glue Inhibitor of SARM1 to Clinic and Announces Appointment of Disarm Therapeutics' Founders to Company's Scientific Advisory Board
Asha Therapeutics (Asha), a life sciences company pioneering breakthrough therapeutics for neurological disease, announced today the company has been awarded a grant from the ALS Association through its Lawrence and Isabel Barnett Drug Development Program for the advancement of ASHA-624, a novel brain-penetrant intra-molecular glue inhibitor of SARM1. The grant will support the continued development of ASHA-624 towards first-in-human clinical trials as a potential disease-modifying therapeutic for Amyotrophic Lateral Sclerosis (ALS). ASHA-624 was designed using Asha's proprietary PRISM™ drug design technology, which creates new medicines to restore normal biology and provide functional cu
11/13/24 9:30:00 AM ET
$LLY
Biotechnology: Pharmaceutical Preparations
Health Care
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer
SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company's global clinical development efforts and serve as a member of Aligos' Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases. "I am excited to welcome Hardean to Aligos a
9/24/24 8:00:00 AM ET
$ALGS
$HAE
$NVO
$PLRX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D. as Chief Development Officer
SAN FRANCISCO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced key leadership appointments to drive its next phase of development and operational success. Blai Coll, M.D., Ph.D., has been promoted to Chief Medical Officer, replacing Mark Bach, M.D., Ph.D. as part of a planned succession, effective September 18. Dr. Coll has served as Vice President of Clinical Development at Structure since 2022, leading the GSBR-1290 program, Structure's oral small molecule GLP-1 agonist that is planned to enter Phase
9/17/24 4:05:00 PM ET
$GPCR
Biotechnology: Pharmaceutical Preparations
Health Care

$GPCR
$LLY
$NVO
Press Releases

Fastest customizable press release news feed in the world

Verge Genomics Announces Milestones in Collaboration with Lilly to Discover and Develop Novel Treatments for ALS
— Lilly to Develop Two Targets Identified and Validated Using Verge Genomics' AI-Enabled, All-in-Human CONVERGE® Platform — Demonstration of the Robust Predictive Power of CONVERGE® - 83% of Prioritized Targets were Validated in Disease-Relevant Models, a Rate Significantly Higher than Industry Standards SOUTH SAN FRANCISCO, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Verge Genomics, a clinical-stage biotechnology company pioneering the use of artificial intelligence (AI) and human data to transform drug discovery and development, announced today that Eli Lilly & Company ("Lilly") (NYSE:LLY) has opted to pursue the development of therapeutics against two validated drug targets for
11/20/24 5:00:00 AM ET
$LLY
Biotechnology: Pharmaceutical Preparations
Health Care
Lilly announces changes on board of directors
INDIANAPOLIS, Nov. 19, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that it has elected Jon Moeller as a new member of its board of directors, effective Dec. 1, 2024. In addition, the company announced that Karen Walker will transition her role with Lilly, resigning as a member of Lilly's board of directors effective Dec. 31, 2024. In 2025, Ms. Walker will collaborate with Lilly on certain digital commercial activities. Mr. Moeller is the chairman of the board, president and chief executive officer of Procter & Gamble (P&G). A strong leader who has served as an integral part of P&G's leadership team for more than two decades, Mr. Moeller has held key positions withi
11/19/24 4:30:00 PM ET
$LLY
Biotechnology: Pharmaceutical Preparations
Health Care
Lilly's muvalaplin lowered lipoprotein(a) levels in adults with high risk for cardiovascular events by up to 85% at highest tested dose
Muvalaplin, an oral, once-daily treatment that inhibits lipoprotein(a) formation via a novel mechanism, achieved positive results in a 12-week Phase 2 study These data were published in the Journal of the American Medical Association (JAMA) and simultaneously presented today at the American Heart Association (AHA) Scientific Sessions 2024 INDIANAPOLIS, Nov. 18, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced positive Phase 2 results for muvalaplin, an investigational once-daily, orally administered selective inhibitor of lipoprotein(a) [Lp(a)], a genetically inherited risk factor for heart disease. The study demonstrated that muvalaplin significantly reduced elevated Lp
11/18/24 2:52:00 PM ET
$LLY
Biotechnology: Pharmaceutical Preparations
Health Care

$GPCR
$LLY
$NVO
FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

May 31, 2024 - FDA Roundup: May 31, 2024
For Immediate Release: May 31, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA approved mRESVIA (Respiratory Syncytial Virus Vaccine) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. mRESVIA is an mRNA-based vaccine that is manufa
5/31/24 3:22:42 PM ET
$LLY
Biotechnology: Pharmaceutical Preparations
Health Care
May 7, 2024 - FDA Roundup: May 7, 2024
For Immediate Release: May 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA announced a meeting of the Psychopharmacologic Drugs Advisory Committee on June 4 to discuss a new drug application for midomafetamine (MDMA) capsules, submitted by Lykos Therapeutics, for the treatment of post-traumatic stress disorder. The committ
5/7/24 4:10:24 PM ET
$LLY
Biotechnology: Pharmaceutical Preparations
Health Care
March 8, 2024 - FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight
For Immediate Release: March 08, 2024 Today, the U.S. Food and Drug Administration approved a new indication for use for Wegovy (semaglutide) injection to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight. Wegovy should be used in addition to a reduced calorie diet and increased physical activity. Cardiovascular disease is a gr
3/8/24 2:00:18 PM ET
$NVO
Biotechnology: Pharmaceutical Preparations
Health Care

Shares of weight loss stocks are trading lower, possibly on continued weakness following recent weight loss data from Roche, which could cause competition concerns for companies in the space.

Chat with this insight

Recent Analyst Ratings for $GPCR$LLY$NVO

$GPCR$LLY$NVO Financials

Live finance-specific insights

Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights

Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity

Lilly reports Q3 2024 financial results highlighted by strong volume-driven revenue growth from New Products

$GPCR$LLY$NVO Leadership Updates

Live Leadership Updates

Asha Therapeutics Awarded Barnett Drug Development Grant by the ALS Association to Advance Novel Intra-Molecular Glue Inhibitor of SARM1 to Clinic and Announces Appointment of Disarm Therapeutics' Founders to Company's Scientific Advisory Board

Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer

Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D. as Chief Development Officer

$GPCR$LLY$NVO Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Walker Karen was granted 303 shares, increasing direct ownership by 5% to 6,249 units (SEC Form 4)

Director Sulzberger Gabrielle was granted 316 shares, increasing direct ownership by 14% to 2,517 units (SEC Form 4)

Director Luciano Juan R was granted 323 shares, increasing direct ownership by 2% to 16,147 units (SEC Form 4)

$GPCR$LLY$NVO SEC Filings

Eli Lilly and Company filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

SEC Form 6-K filed by Novo Nordisk A/S

SEC Form 6-K filed by Novo Nordisk A/S

$GPCR$LLY$NVO Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Structure Therapeutics Inc.

SEC Form SC 13G filed by Structure Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Structure Therapeutics Inc.

$GPCR$LLY$NVO Market Insights

Live Market Insights

$GPCR$LLY$NVO Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Novo Nordisk's Options Frenzy: What You Need to Know

Here's How Much You Would Have Made Owning Eli Lilly and Co Stock In The Last 15 Years

Eli Lilly and Novo Nordisk shares are trading lower after competitor Viking announced the advancement of its obesity candidate.

Wolfe Research initiated coverage on Eli Lilly with a new price target

Bernstein initiated coverage on Eli Lilly with a new price target

Morgan Stanley initiated coverage on Structure Therapeutics with a new price target

$GPCR$LLY$NVO Press Releases

Fastest customizable press release news feed in the world

Verge Genomics Announces Milestones in Collaboration with Lilly to Discover and Develop Novel Treatments for ALS

Lilly announces changes on board of directors

Lilly's muvalaplin lowered lipoprotein(a) levels in adults with high risk for cardiovascular events by up to 85% at highest tested dose

$GPCR$LLY$NVO FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

May 31, 2024 - FDA Roundup: May 31, 2024

May 7, 2024 - FDA Roundup: May 7, 2024

March 8, 2024 - FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight

Recent Analyst Ratings for
$GPCR
$LLY
$NVO

$GPCR
$LLY
$NVO
Financials

$GPCR
$LLY
$NVO
Leadership Updates

$GPCR
$LLY
$NVO
Insider Trading

$GPCR
$LLY
$NVO
SEC Filings

$GPCR
$LLY
$NVO
Large Ownership Changes

$GPCR
$LLY
$NVO
Market Insights

$GPCR
$LLY
$NVO
Analyst Ratings

$GPCR
$LLY
$NVO
Press Releases

$GPCR
$LLY
$NVO
FDA approvals